Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC) Meeting Abstract
| Authors: | Choueiri, T. K.; Plimack, E. R.; Powles, T.; Voss, M. H.; Gurney, H.; Silverman, R. K.; Perini, R. F.; Rodriguez-Lopez, K.; Rini, B. I. |
| Abstract Title: | Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC) |
| Meeting Title: | 2022 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2022 Feb 17-19 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-20 |
| Language: | English |
| ACCESSION: | WOS:000771008900404 |
| DOI: | 10.1200/JCO.2022.40.6_suppl.TPS399 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS399 -- Meeting was conducted online as well as in person -- Source: Wos |
